Nutraceuticals under the spotlight

Article

Lutein, beta-carotene, zeaxanthin, astaxanthin, bilberry are eye health ingredients under the spotlight in a new European Health Ingredients Market report.

According to the study's authors, business analysts, Frost & Sullivan: “The rising prevalence of lifestyle-linked eye diseases has caused the global food ingredients market to leverage the consumer s need to protect their eyes through enhanced nutrition.

“The focus on eye health has become a primary concern in today's health conscious food industry. Eye health is a key component of a healthy life and the market for eye health ingredients witnessed growth in 2007, spurred by the incidence of eye-diseases such as glaucoma, age-related macular degeneration, cataracts, and childhood blindness. As a result of the scale of visual impairment problems, many consumers are making lifestyle changes, switching to nutrient-rich diets that will aid in protecting visual acuity, preventing cataract and blindness, and safeguarding their eyesight from harmful exposure to ultraviolet rays. Since 2007, the European market for eye health ingredients has been dominated by antioxidants. Key eye health ingredients in use in 2007 included lutein, beta-carotene and zeaxanthin.”

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.